500-Patient GP Trial Tests Blood-Based Alzheimer's Diagnosis

The burden of dementia on primary care is immense, yet GPs have long lacked reliable tools to diagnose Alzheimer's without specialist referrals. Scotland's BriDGe study puts a simple blood test into the hands of community doctors, potentially enabling earlier intervention and better resource management across the healthcare system.

Scotland has launched the largest UK study of Alzheimer’s blood tests in general practice, aiming to move diagnosis from specialist memory clinics into the community. The BriDGe (Bringing Alzheimer’s Disease Biomarkers to General Practice) study, led by Scottish Brain Sciences, will enroll up to 500 patients across more than 50 GP surgeries in central and northern Scotland. It will evaluate two blood-based biomarkers—p-tau181 and p-tau217—developed by Roche Diagnostics, which detect phosphorylated tau proteins linked to the brain changes of Alzheimer’s disease. The study’s launch on July 15, 2026, capitalizes on growing international evidence that these biomarkers can identify or rule out Alzheimer’s earlier and more accurately than many existing memory tests or brain scans.

“

In Scotland, an estimated 90,000 people live with dementia, roughly 60,000 of whom have Alzheimer’s, yet diagnosis often occurs late, with long waits for specialist assessments.

This trial is a pragmatic attempt to address a critical gap in dementia care. In Scotland, an estimated 90,000 people live with dementia, roughly 60,000 of whom have Alzheimer’s, yet diagnosis often occurs late, with long waits for specialist assessments. Primary care physicians, the first point of contact for most patients with cognitive complaints, currently lack objective tools to distinguish Alzheimer’s from other dementias or age-related decline. The BriDGe study will generate real-world evidence on how blood tests perform when integrated into routine GP workflows, measuring not just diagnostic accuracy but also impact on care decisions, referral patterns, and patient outcomes.

The p-tau217 assay, in particular, has shown high sensitivity and specificity in previous cohort studies, correlating strongly with amyloid PET imaging—the current gold standard—and can detect pathology years before symptom onset. By bringing this capability to GPs, the trial could dramatically shorten the diagnostic odyssey, enabling earlier access to emerging disease-modifying therapies like lecanemab and donanemab, which require confirmation of amyloid or tau pathology. Moreover, early diagnosis empowers patients to make lifestyle changes, access support services, and plan for the future, as highlighted by Dr Sheelagh Harwell, a participating GP in Edinburgh, who noted that consultations are shifting from discussing dementia risk to brain health. A patient named Martin, who previously experienced uncertainty during diagnosis, underscores the human toll of delayed clarity.

Roche Diagnostics’ backing is strategically significant. The company already markets Elecsys immunoassays for cerebrospinal fluid biomarkers and is advancing blood-based assays for global regulatory approval. Positive results from BriDGe would bolster its submission package for the European Medicines Agency and the UK’s MHRA, potentially establishing blood testing as a first-line screening tool. For the diagnostics industry, winning over primary care is essential to scaling accessibility—and reimbursement—for Alzheimer’s testing beyond research hospitals. The Scottish study positions Roche at the forefront of this transformation, though competitors like C2N Diagnostics and Quanterix are also pursuing blood-based panels.

From a health-system perspective, the BriDGe study carries significant implications for resource allocation. The NHS in Scotland, like many health systems, faces a shortage of dementia specialists and an aging population that will only increase prevalence. If blood tests can safely rule out Alzheimer’s in a primary care setting, it could reduce unnecessary referrals by an estimated third, according to previous modeling. This would redirect specialist resources to complex cases, reduce patient wait times from months to days, and lower overall diagnostic costs per case. The study will also collect data on GP confidence and training needs, crucial for any nationwide roll-out.